Intrahepatic cholangiocarcinoma: review and update

Abstract

Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies that could develop at any level from the biliary tree. CCA is currently classified into intrahepatic (iCCA), perihilar and distal on the basis of its anatomical location. Of note, these three CCA subtypes have common features but also important inter-tumor and intra-tumor differences that can affect the pathogenesis and outcome. A unique feature of iCCA is that it recognizes as origin tissues, the hepatic parenchyma or large intrahepatic and extrahepatic bile ducts, which are furnished by two distinct stem cell niches, the canals of Hering and the peribiliary glands, respectively. The complexity of iCCA pathogenesis highlights the need of a multidisciplinary, translational and systemic approach to this malignancy. This review will focus on the advances of iCCA epidemiology, histo-morphology, risk factors, molecular pathogenesis, revealing the existence of multiple subsets of iCCA.

Keywords

Cholangiocarcinoma / classifications / inflammation / cells of origin / stem cells / molecular profiling

References

[1] Bridgewater J,Khan SA,Park JW,Pawlik TM.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.J Hepatol2014;60:1268-89

[2] Blechacz B,Roskams T.Clinical diagnosis and staging of cholangiocarcinoma.Nat Rev Gastroenterol Hepatol2011;8:512-22 PMCID:PMC3331791

[3] Banales JM,Carpino G,Andersen JB,Lind GE,Forbes SJ,Geier A,Mertens JC,Benedetti A,Vaquero J,Raggi C,Gaudio E,Marin JJ.Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).Nat Rev Gastroenterol Hepatol2016;13:261-80

[4] Komuta M,Vandecaveye V,Van Steenbergen W,Laleman W,Aerts R,Nevens F,Roskams T.Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes.Hepatology2012;55:1876-88

[5] Aishima S.Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type.J Hepatobiliary Pancreat Sci2015;22:94-100

[6] Rizvi S.Pathogenesis, diagnosis, and management of cholangiocarcinoma.Gastroenterology2013;145:1215-29 PMCID:PMC3862291

[7] Andersen JB,Blechacz BR,Komuta M,Conner EA,Roskams T,Factor VM.Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.Gastroenterology2012;142:1021-31 PMCID:PMC3413201

[8] Nakamura H,Totoki Y,Elzawahry A,Hama N,Urushidate T,Hiraoka N,Shimada K,Kosuge T,Shibata T.Genomic spectra of biliary tract cancer.Nat Genet2015;47:1003-10

[9] Nakanuma Y,Harada K,Xu J.Pathological classification of intrahepatic cholangiocarcinoma based on a new concept.World J Hepatol2010;2:419-27 PMCID:PMC3010511

[10] Cardinale V,Reid L,Alvaro D.Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity.World J Gastrointest Oncol2012;4:94-102 PMCID:PMC3360107

[11] England Rare and less common cancers: Incidence and Mortality in, 2010-2013. A Report from Pubblic Health England, National Cancer Registration and Analysis Service. Available from: http://www.ncin.org.uk/publications/rare_and_less_common_cancers. [Last accessed on 8 Jun]

[12] Bertuccio P,Levi F,Negri E.A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe.Ann Oncol2013;24:1667-74

[13] Lepage C,Hackl M,Molina E,Sant M,Faivre J.Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: results of EUROCARE-5.Eur J Cancer2015;51:2169-78

[14] Smittenaar CR,Stewart K.Cancer incidence and mortality projections in the UK until 2035.Br J Cancer2016;115:1147-55 PMCID:PMC5117795

[15] Llovet JM,Lachenmayer A.Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Nat Rev Clin Oncol2015;12:408-24

[16] Varadhachary GR.Cancer of unknown primary site.N Engl J Med2014;371:757-65

[17] Alvaro D,Benedetti A,Fava G,Marzioni M,Strazzabosco M," AISF,committee .Cholangiocarcinoma in Italy: a national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease..Dig Liver Dis2011;43:60-5

[18] Farges O,Le Treut YP,Laurent A,Nuzzo G,Pruvot FR.AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectableintrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group.Cancer2011;117:2170-7

[19] Liau JY,Yuan RH,Lee HJ.Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features.Mod Pathol2014;27:1163-73

[20] Nakanuma Y,Harada K,Sasaki M,Kim J.Pathological spectrum of intrahepatic cholangiocarcinoma arising in non biliary chronic advanced liver diseases.Pathol Int2011;61:298-305

[21] Komuta M,Vander Borght S,Verslype C,Yano H,Matsuda M,Desmet VJ,Roskams T.Clinicopathological study on cholangiolocellular carcinomasuggesting hepatic progenitor cellorigin.Hepatology2008;47:1544-56

[22] Carpino G,Onori P,Berloco PB,Wang Y,Anceschi M,Alvaro D,Gaudio E.Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages.J Anat2012;220:186-99 PMCID:PMC3275774

[23] Theise ND,Portmann BC,Yee H,Kumar A.The canals of Hering and hepatic stem cells in humans.Hepatology1999;30:1425-33

[24] Kuwahara R,Landis CS,Barendswaard E.The hepatic stem cell niche: identification by label-retaining cell assay.Hepatology2008;47:1994-2002 PMCID:PMC2847183

[25] Schmelzer E,Bruce A,Ludlow J,Moss N,McClelland R,Kulik M,Tallheden T,Furth ME.Human hepatic stem cells from fetal and postnatal donors.J Exp Med2007;204:1973-87 PMCID:PMC2118675

[26] Cardinale V,Carpino G,Gatto M,Berloco PB,Wauthier E,Inverardi L,Ricordi C,Gaudio E,Reid L.Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets.Hepatology2011;54:2159-72

[27] Turner R,Wang Y,Gaudio E,Mendel G,Barbier C,Reid LM.Human hepatic stem cell and maturational liver lineage biology.Hepatology2011;53:1035-45 PMCID:PMC3066046

[28] Farshidfar F,Gingras MC,Shih J,Hinoue T,Gibb EA,Covington KR,Shinbrot E,Hegde A,Reznik E,Pedamallu CS,Hess JM,Rhie SK,Borad MJ,Zhu AX,Sander C,Cherniack AD,Mounajjed T,Torbenson MS,Laird PW,McRee AJ,Andersen JB,Roberts LR.Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles.Cell Rep2017;18:2780-94 PMCID:PMC5493145

[29] Fitzmaurice C,Pain A,Moradi-Lakeh M,Allen C,Woodbrook R,Hamadeh RR,Werdecker A,Te Ao B,Karimkhani C,Cooke GS,Carpenter DO,Nash D,De Leo D,Ukwaja KN,Yun Jin K,Mills E,Catalá-López F,Gotay C,Hosgood HD3rd,Leasher JL,Leigh J,Sanabria J,Jacobsen KH,Franklin RC,Montico M,Tonelli M,Petzold M,Younis M,Breitborde N,Pourmalek F,Esteghamati A,Ali R,Malekzadeh R,Weintraub R,Hay R,Westerman R,Nolte S,Weichenthal S,Fereshtehnejad SM,Driscoll T,Alsharif U,Vlassov VV,Mekonnen W,Yano Y,Campos I,Mueller U,Trillini M,Williams HC,Dandona R,Cowie B,Antonio CA,van Gool CH,Oh IH,Soreide K,Kereselidze M,Cardenas R,Tillmann T,Krueger H,Dey S,Hafezi-Nejad N,Sreeramareddy CT,Wang H,Mokdad A,Lozano R,Forouzanfar M,Murray C.The global burden of cancer 2013.JAMA Oncol2015;1:505-27

[30] Poomphakwaen K,Kamsa-Ard S,Chaveepojnkamjorn W,Sujirarat D.Risk factors for cholangiocarcinoma in Khon Kaen, Thailand: a nested case-control study.Asian Pac Cancer Prev2009;10:251-8

[31] Shin HR,Masuyer E,Bouvard V,Wiangnon S,Hong ST.Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma--focus on East and South-Eastern Asia.Asian Pac J Cancer Prev2010;11:1159-66

[32] Sripa B,Sithithaworn P,Laha T,Pairojkul C,Tesana S,Bethony JM,Brindley PJ.Liver fluke induces cholangiocarcinoma.PLoS Med2007;4:e201 PMCID:PMC1913093

[33] Lepage C,Hackl M,Molina E,Sant M,Faivre J.Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: results of EUROCARE-5.Eur J Cancer2015;51:2169-78

[34] Donato F,Tagger A,Ribero ML,Martelli C,Trevisi P.Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy.Cancer Causes Control2001;12:959-64

[35] Tao LY,Qu Q,Liu W,Zhang SM.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a case-control study in China.Liver Int2010;30:215-21

[36] Welzel TM,El-Serag HB,Hsing AW,McGlynn KA.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.Clin Gastroenterol Hepatol2007;5:1221-8 PMCID:PMC2083573

[37] Yamamoto S,Hai S,Yamamoto T,Takemura S,Yamazaki O,Tanaka T.Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma.Cancer Sci2004;95:592-5

[38] Lee TY,Jung SW,Yun SC,Kwon S,Seo DW,Suh DJ.Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study.Am J Gastroenterol2008;103:1716-20

[39] Shaib YH,Nooka AK,Brown TD,Hassan MM.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study.Am J Gastroenterol2007;102:1016-21

[40] Zhou YM,Yang JM,Shao WY,Wang YL.Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China.World J Gastroenterol2008;14:632-5 PMCID:PMC2681159

[41] Lee CH,Lin YJ,Chen MF.Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma.Br J Cancer2009;100:1765-70 PMCID:PMC2695699

[42] Choi D,Lee KT,Heo JS,Lee NY,Hong ST.Cholangiocarcinoma and Clonorchis sinensis infection: a case-control study in Korea.J Hepatol2006;44:1066-73

[43] Zhou H,Zhou D,Wang Q,Tu Q,Hu H.Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis.Eur J Cancer2010;46:1056-61

[44] Welzel TM,Zeuzem S,Davila JA.Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in SEER-Medicare database.Hepatology2011;54:463-71 PMCID:PMC4141525

[45] Zhou Y,Lin Q,Gong Y,Yu M,Li K,Li Z.Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood group, hepatitis B virus and their synergism.Int J Cancer2013;15:1867-75

[46] Brandi G,Farioli A,Curti S,Ercolani G,Biasco G.Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis.Cancer Causes Control2013;24:911-8 PMCID:PMC3631123

[47] Patel T.Cholangiocarcinoma—controversieses and challenges..Nat Rev Gastroenterol2011;8189-200

[48] Broomé U,Lööf L,Hultcrantz R,Prytz H,Wallerstedt S.Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.Gut1996;38:610-5 PMCID:PMC1383124

[49] Farrant JM,Wilkinson ML,Portmann BC,Williams R.Natural history and prognostic variables in primary sclerosing cholangitis.Gastroenterology1991;100:1710-7

[50] Rosen CB,Wiesner RH,LaRusso NF.Cholangiocarcinoma complicating primary sclerosing cholangitis.Ann Surg1991;213:21-5 PMCID:PMC1358305

[51] Erichsen R,Vilstrup H,Sørensen HT.Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003.Eur J Epidemiol2009;24:513-20

[52] Chapman MH,Bannoo S,Wittmann J.Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience.Eur J Gastroenterol Hepatol2012;24:1051-8 PMCID:PMC3584158

[53] Bergquist A,Olsson R,Lööf L,Hultcrantz R,Prytz H,Almer S,Broomé U.Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.J Hepatol2002;36:321-7

[54] Chapman R,Kalloo A,Boberg KM,Gores GJ.Diagnosis and management of primary sclerosing cholangitis.Hepatology2010;51:660-78

[55] Claessen MM,Tytgat KM,van Buuren HR.High lifetime risk of cancer in primary sclerosing cholangitis.J Hepatol2009;50:158-64

[56] Carpino G,Renzi A,Berloco PB,Karlsen TH,Gaudio E.Activation of biliary tree stem cells within peribiliary glands in primary sclerosing cholangitis.J Hepatol2015;63:1220-8

[57] Huai JP,Ye XH.Inflammatory bowel disease and risk of cholangiocarcinoma: evidence from a meta-analysis of population-based studies.Asian Pac J Cancer Prev2014;15:3477-82

[58] Weismüller TJ,Bergquist A,Lenzen H,Holm K,Färkkilä MA,Thorburn D,Fevery J,Chazouillères O,Lazaridis KN,Pereira SP,Mason A,Bowlus CL,Halilbasic E,Milkiewicz P,Huynh DK,Manser CN,Invernizzi P,Kirchner GI,Zimmer V,Braun F,Juran BD,Rupp C,Benito de Valle M,Cheung A,Schramm C,Karlsen TH,Strassburg CP,K4 Lindor,Hansen BE,International PSC Study Group..Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis.Gastroenterology2017;152:1975-84 PMCID:PMC5546611

[59] Tyson GL.Risk factors for cholangiocarcinoma.Hepatology2011;54:173-84 PMCID:PMC3125451

[60] Tiwari SK,Ibrahim M,Habibullah CM.Helicobacter pylori and other Helicobacter species DNA in human bile samples from patients with various hepatobiliary diseases.World J Gastroenterol2006;12:2181-6 PMCID:PMC4087643

[61] Bulajic M,Schneider-Brachert W,Reischl U,Lehn N,Löhr M.Helicobacter pylori and the risk of benign and malignant biliary tract disease.Cancer2002;95:1946-53

[62] Chang JS,Chen LT.Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study.PLoS One2013;8:e69981 PMCID:PMC3718690

[63] Pandey M.Helicobacter species are associated with possible increase in risk of hepatobiliary tract cancers.Surg Oncol2009;18:51-6

[64] Murphy G,Taylor PR,Weinstein SJ,Parisi D,Butt J,Koshiol J,Lai GY,Dawsey SM.Association of seropositivity to Helicobacter species and biliary tract cancer in the ATBC study.Hepatology2014;60:1963-71 PMCID:PMC4216769

[65] Kaewpitoon SJ,Rujirakul R,Matrakool L,Kootanavanichpong N,Kompor P,Kujapun J,Ponphimai S,Polsripradist P,Phatisena T.Helicobacter species are possible risk factors of cholangiocarcinoma.Asian Pac J Cancer Prev2016;17:37-44

[66] Leelawat K,Leelawat S.Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients.Southeast Asian J Trop Med Public Health2007;38:881-5

[67] Sithithaworn P,Duenngai K,Pairojkul C.Roles of liver fluke infection as risk factor for cholangiocarcinoma.J Hepatobiliary Pancreat Sci2014;21:301-8

[68] Xia J,Peng HJ.Association between liver fluke infection and hepatobiliary pathological changes: a systematic review and meta-analysis.PLoS One2015;10:1-19 PMCID:PMC4506038

[69] Li J,Xu L.Diabetes mellitus and the risk of cholangiocarcinoma: an updated meta-analysis.Prz Gastroenterol2015;10:108-17

[70] Shaib YH,Davila JA,McGlynn KA.Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study.Gastroenterology2005;128:620-6

[71] Huang YJ,Chiou YH,Meng TC,Yen Y.Interactive role of diabetes mellitus and female sex in the risk of cholangiocarcinoma: a population-based nested case–control study.Oncotarget2017;8:6642-51

[72] Carpino G,Cardinale Renzi A V,Nevi L,Berloco PB,Reid LM,Gaudio E.Peribiliary glands as a niche of extrapancreatic precursors yielding insulin-producing cells in experimental and human diabetes.Stem Cells2016;34:1332-42

[73] Chaiterakij R,Harmsen WS,Mettler TA,Kim WR,Roberts RO,Therneau TM.Risk factor for intrahepatic cholangiocarcinoma association between metformin use and reduced cancer risk.Hepatology2013;57:648-55 PMCID:PMC3565026

[74] Ling S,Ke Q,Li L,Dong C,Xu F,Wang L.Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines.Oncol Rep2014;31:2611-8

[75] Palmer WC.Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma.J Hepatol2012;57:69-76 PMCID:PMC3804834

[76] Reddy SK,Marsh JW,Paul A,Marques H,Barroso E,Geller DA,Herlea V,Anders R,Gigot JF,Pawlik TM.Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma.J Gastrointest Surg2013;17:748-55 PMCID:PMC4007003

[77] Shin HR,Park HJ,Chung JM,Ahn YO.Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea.Int J Epidemiol1996;25:933-40

[78] Li H,Zhou ZQ,Zhang ZY.Hepatitis C virus infection and the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis of 16 case-control studies.World J Surg Oncol2015;13:161-8 PMCID:PMC4419416

[79] Plentz RR.Clinical presentation, risk factors and staging systems of cholangiocarcinoma.Best Pract Res Clin Gastroenterol2015;29:245-52

[80] Zhou HB,Hu HP.Hepatitis B virus infection and intrahepatic cholangiocarcinoma.World J Gastroenterol2014;20:5721-9 PMCID:PMC4024782

[81] Zhang H,He Z,Wenting Z.HBV infection status and the risk of cholangiocacinoma in Asia: a meta-analysis.Bio Med Research International2016;2016:3417976

[82] Cardinale V,Alvaro D.New Insights into Epidemiology of Cholangiocarcinoma..In: Brandi G, Ercolani G, editors. Cholangiocarcinoma.2015;Nova Science Pub19-38

[83] Cardinale V.Molecular Profiling..In: Herman J, Pawlik T, Thomas CR Jr, editors. Biliary Tract and Gallbladder Cancer: A Multidisciplinary Approach, 2nd Edition.2013;Springer Science Pub99-115

[84] Jiao Y,Anders RA,Streppel MM,Niknafs N,Maitra A,Offerhaus GJA,Roberts LR,Popescu I,Dima S,Simbolo M,Capelli P,Ruzzenente A,Tortora G,Scarpa A,Klimstra D,Velculescu VE,Vogelstein B,Papadopoulos N.Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.Nat Genet2013;45:1470-3 PMCID:PMC4013720

[85] Ong CK,Pairojkul C,Cutcutache I,McPherson JR,Ng CC,Myint SS,Heng HL,Zang ZJ,Wu J,Huang D,Chan-on W,Qian CN,Ooi A,Furge K,Sripa B,Yongvanit P,Bhudhisawasdi V,Tan P.Exome sequencing of liver fluke-associated cholangiocarcinoma.Nat Genet2012;44:690-3

[86] Zou S,Zhou H,Frech C,Chu JS,Li Y,Wang H,Kong G,Ding C,Hu H.Mutational landscape of intrahepatic cholangiocarcinoma.Nat Commun2014;5:5696

[87] Borad MJ,Egan JB,Fonseca R,McCullough AE,Hunt K,Young SW,Silva AC,Block M,Lazaridis KN,Bible KC,Oliver GR,Nair AA,Asmann Y,Schahl K,Barr Fritcher EG,J4 Aldrich,Izatt T,Cherni I,Reiman R,McDonald J,Mastrian SD,Watanabe AT,Han H,Craig DW,Carpten JD.Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.PLoS Genet2014;10:e1004135 PMCID:PMC3923676

[88] Fujimoto A,Shiraishi Y,Kawakami Y,Nakamura T,Ariizumi S,Shigemizu D,Boroevich KA,Sasaki A,Maejima K,Tanaka H,Shibata T,Shimada K,Shigekawa Y,Ohdan H,Yamada T,Ishikawa O,Yamaue H,Miyano S,Nakagawa H.Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity.Nat Commun2015;6:6120

[89] Gao Q,Wang XY,Gao S,Shi JY,Wang ZC,Shi YH,Ding ZB,Dai Z,Wang H,Chen ZA,Qiu SJ,He XH.Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.Gastroenterology2014;146:1397-407

[90] Boulter L,Kendall TJ,Wojtacha D,Ridgway RA,Van Rooijen N,Wigmore SJ,Forbes SJ.WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited.J Clin Invest2015;125:1269-85 PMCID:PMC4362247

[91] Chan-On W,Ong CK,Dima S,Lim KH,Cutcutache I,Ooi L,Chow P,Lee SY,Tan IBH,Nastase A,Wong BH,Rajasegaran V,Nagarajan S,Zhang S,Yu W,Sithithaworn P,Wongkham S,Bhudhisawasdi V,Rozen SG,Teh BT.Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.Nat Genet2013;45:1474-8

[92] Sia D,Moeini A,Hao K,Bonal D,Zhang Z,Cornella H,Pinyol R,Roayaie S,Fuster J,Waxman S,Schadt E,Llovet JM.Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.Nat Commun2015;6:6087

[93] Nault JC.Genetics of hepatobiliary carcinogenesis.Semin Liver Dis2011;31:173-87

[94] Chen CP.Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics.Expert Rev Mol Diagn2010;10:883-95

[95] Kumar M,Wang XW.Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?.Cell Biosci2011;1:5 PMCID:PMC3116244

[96] Yoon JH,Werneburg NW,Gores GJ.Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line.Gastroenterology2002;122:985-93

[97] Yoon JH,Werneburg NW,Gores GJ.Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis.Hepatology2004;39:732-8

[98] Jaiswal M,Burgart LJ.Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism.Cancer Res2000;60:184-90

[99] Jaiswal M,Shapiro RA,Gores GJ.Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes.Gastroenterology2001;120:190-9

[100] Ishimura N,Gores GJ.Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth.Am J Physiol Gastrointest Liver Physiol2004;287:G88-95

[101] Seol MA,Lee MJ,Cui XD,Ahn EK,Kim IH.Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma.BMC Cancer2011;11:78 PMCID:PMC3053267

[102] Jinawath N,Furukawa Y,Tsunoda T,Pairojkul C.Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma.Hepatology2006;44:1025-38

[103] Wang X,Huang Y,Men J,Luo F,Lv X,Zhou C,Li X,Hu Y,Hu X,Yu X.The draft genome of the carcinogenic human liver fluke Clonorchis sinensis.Genome Biol2011;12:R107 PMCID:PMC3333777

[104] Young ND,Hall RS,Cantacessi C,Sohn WM,Loukas A,Gasser RB.Unlocking the transcriptomes of two carcinogenic parasites, Clonorchis sinensis and Opisthorchis viverrini.PLoS Negl Trop Dis2010;4:e719 PMCID:PMC2889816

[105] Sriraksa R,El-Bahrawy MA,Daduang J,Chau-In S,Limpaiboon T.CpG-island methylation study of liver fluke-related cholangiocarcinoma.Br J Cancer2011;104:1313-8 PMCID:PMC3078588

[106] Sakoda LC,Chen BE,Rosenberg PS,Deng J,Wang BS,Zhang BH,Yeager M,Chanock S,Hsing AW.Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China.Carcinogenesis2006;27:1251-6

[107] Kipp BR,Clayton AC,Roberts LR,Levy MJ.Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography.J Mol Diagn2010;12:780-6 PMCID:PMC2963905

[108] Huang L,Liang LJ.Aberrant DNA methylation profile in cholangiocarcinoma.World J Gastrointest Pathophysiol2010;1:23-9 PMCID:PMC3097943

[109] Huang L,Rao A,Chen W,Yin XY,Culbreath B,Quinn M,Bradley M,DeMorrow S.Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events.Lab Invest2012;92:1451-60 PMCID:PMC3959781

[110] Melum E,Schrumpf E,Thorsby E,Lie BA.Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms.Hepatology2008;47:90-6

[111] Karamitopoulou E,Zlobec I,Carafa V,Schaffner T,Diamantis I,Terracciano L.Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas.Am J Clin Pathol2008;130:780-6

[112] Miller G,Dhall D,DeMatteo RP,Singh B,Blumgart LH,Jarnagin WR.Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract.J Exp Clin Cancer Res2009;28:62 PMCID:PMC2698861

[113] Borger DR,Fan KC,Fantin VR,Schenkein DP,Ancukiewicz M,Kwak EL,Ryan DP,Dias-Santagata D,Zhu AX.Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.Oncologist2012;17:72-97 PMCID:PMC3267826

[114] Yang B,Guo M,Clark DP.Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma.Mod Pathol2005;18:412-20

[115] Oliveira DV,Chen X,Andersen JB.Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.Expert Rev Gastroenterol Hepatol2017;11:349-56

[116] Rhee H,Chung T,Kwon SM,Seok JY,Choi JS,Andersen JB,Woo HG.Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.Liver Int2018;38:113-24

[117] Rizvi S.Emerging molecular therapeutic targets for cholangiocarcinoma.J Hepatol2017;67:632-44

[118] NakanumaY.Cystic and papillary neoplasm involving peribiliary glands: a biliary counterpart of branch-type intraductal papillary mucinous [corrected] neoplasm?.Hepatology2012;55:2040-1

[119] Cardinale V,Carpino G,Alpini G,Reid LM.The biliary tree--a reservoir of multipotent stem cells.Nat Rev Gastroenterol Hepatol2012;9:231-40

[120] Cardinale V,Carpino G,Bragazzi MC,DeRose AM,Onori P,Franchitto A,Grazi G,D'Argenio G,Reid LM,Alvaro D.Profiles of cancer stem cell subpopulations in cholangiocarcinomas.Am J Pathol2015;185:1724-39 PMCID:PMC4450332

[121] Gandou C,Sato Y,Sasaki M,Nakanuma Y.Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules.Hum Pathol2013;44:811-21

[122] Nakanuma Y,Sasaki M.Proposal of a new disease concept "biliary diseases with pancreatic counterparts." Anatomical and pathological bases..Histol Histopathol2014;29:1-10

[123] Cardinale V,Alvaro D.Clinical features of intrahepatic cholangiocarcinoma..In: Brandi G, Ercolani G, editors. Cholangiocarcinoma.2015;Nova Science Pub125-34

[124] Rimola J,Reig M,de Lope CR,Bruix J.Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.Hepatology2009;50:791-8

[125] Iavarone M,Vavassori S,Sangiovanni A,Forzenigo LV,Bolondi L.Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis.J Hepatol2013;58:1188-93

[126] Kim SJ,Han JK,Lee JY.Peripheral mass-forming cholangiocarcinoma in cirrhotic liver.AJR Am J Roentgenol2007;189:1428-34

[127] Weber SM,O'Reilly EM,Miyazaki M.Intrahepatic cholangiocarcinoma: expert consensus statement.HPB (Oxford)2015;17:669-80 PMCID:PMC4527852

[128] Chen J,Deng M,Shi J,Sun Q,Fan XS,Huang Q.Clinicopathologic, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type.Hum Pathol2017;64:118-27

[129] Khan SA,Goldin RD,Karani J,Rosenberg WM,Taylor-Robinson SD,Thomas HC,Gastroenterology British Society of.Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update.Gut2012;61:1657-69

[130] Bledsoe JR,Deshpande V.Difficult diagnostic problems in pancreatobiliary neoplasia.Arch Pathol Lab Med2015;139:848-57

[131] European Association for the Study of the Liver.EASL Clinical Practice Guidelines: management of cholestatic liver diseases.J Hepatol2009;51:237-67

[132] Lindor KD,Harrison ME.ACG clinical guideline: primary sclerosing cholangitis.Am J Gastroenterol2015;110:646-59; quiz 660

[133] Navaneethan U,Lourdusamy V,Vargo JJ.Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis.Gastrointest Endosc2015;81:168-76 PMCID:PMC4824293

[134] Arbelaiz A,Krawczyk M,Lapitz A,Erice O,Jimenez-Agüero R,Ibarra C,Jimeno JP,Milkiewicz P,Macias RIR,Patel T,Martinez I,Falcon-Perez JM,Banales JM.Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.Hepatology2017;66:1125-43

[135] Alvaro D.The challenge of cholangiocarcinoma diagnosis: the turning point is in extracellular vesicles?.Hepatology2017;66:1029-31

[136] Primrose JN,Palmer DH,Mirza D,Corrie P,Wasan HS,Wall LR,Evans TRJ,Praseedom R,Garden OJ,Valle JW.Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study..J Clin Oncol2017;35 Suppl 15:abstr4006

[137] Javle M,Shroff RT,Springfeld C,Ramanathan RK,Sadeghi S,El-Khoueiry A,Borbath I,Oh DY,Chen LT,Van Cutsem E,Ciombor K,Patel A,Porter D,Zhu AX,Bekaii-Saab T.Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma.J Clin Oncol2018;36:276-82

[138] Bragazzi MC,Safarikia S,Costantini D,Cardinale V.New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin.Ann Gastroenterol2018;31:42-55

[139] Rycaj K.Cell-of-origin of cancer versus cancer stem cells: assays and interpretations.Cancer Res2015;75:4003-11 PMCID:PMC4756645

[140] Visvader JE.Cells of origin in cancer.Nature2011;469:314-22

[141] Cardinale V,Carpino G,Gaudio E.Mucin producing cholangiocarcinoma might derive from biliarytree stem/progenitor cells located in peribiliary glands.Hepatology2012;55:2041-2

[142] Yamashita T.Cancer stem cells in the development of liver cancer.J Clin Invest2013;123:1911-8 PMCID:PMC3635728

[143] Raggi C,Andersen JB.Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts.J Hepatol2015;62:198-207

[144] Chen WT,Pfaffenbach K,Luo B,Lee AS.Liver-specific knockout of GRP94 in mice disrupts cell adhesion, activates liver progenitor cells, and accelerates liver tumorigenesis.Hepatology2014;59:947-57 PMCID:PMC4214272

[145] Vander Borght S,Libbrecht L,Aerts R,Verslype C,Roskams T.Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin.Liver Int2008;28:1370-80

[146] Govaere O,Berkers J,Janssen C,Katoonizadeh A,van Kempen LC,Verslype C,Rogiers V,Topal B,Vankelecom H,van den Oord J,Roskams T.Keratin 19: a key role player in the invasion of human hepatocellular carcinomas.Gut2014;63:674-85 PMCID:PMC3963546

[147] Magee JA,Morrison SJ.Cancer stem cells: impact, heterogeneity, and uncertainty.Cancer Cell2012;21:283-96 PMCID:PMC4504432

[148] Moeini A,Zhang Z,Stueck A,Montal R,Martinez-Quetglas I,Hao K,Thung SN,Llovet JM.Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.J Hepatol2017;66:952-61

[149] Wei M,Lin P,Quan Z.Multiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma.Cancer Letters2016;379:253-61